Janet Dancey

Overview

Dr. Janet Dancey is the leader of the Canadian Cancer Clinical Trials Network (3CTN) and the Director of the Canadian Cancer Trials Group. 3CTN is a pan-Canadian initiative to improve the efficiency and quality of clinical trials in Canada. 3CTN will provide support and coordination for a network of teams at cancer treatment centres and hospitals. With regional participation, 3CTN will enable sites to increase their capacity and capability to conduct academic trials.

Contact Information

Dr. Janet Dancey

janet [dot] danceyatoicr [dot] on [dot] ca

Telephone: 416-673-6532

Affiliations

2014 - Director, Canadian Cancer Clinical Trials Group.
2013 - Scientific Director, Canadian Cancer Clinical Trials Network (3CTN).
2008 - Clinician-Scientist I, Ontario Institute for Cancer Research (OICR).
2008 - Professor, Department of Oncology, Queen's University.
2008 - Chair, Experimental Therapeutics Network, Cancer Care Ontario (CCO).
2008 - 2015Program Director, High Impact Clinical Trials, Ontario Institute for Cancer Research (OICR).
2007 - 2008Associate Chief, Investigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute.
1999 - 2007Senior Clinical Investigator, Investigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute.
1997 - 1999Assistant Professor, Faculty of Medicine, University of Toronto.
1996 - 1999Active Staff, Department of Medicine, Division of Hematology/Oncology, The Toronto Hospital/Ontario Cancer Institute/ Princess Margaret Cancer Centre.
1995Clinical Research Fellow, Institut Gustave Roussy. Supervisor: Dr Thierry Le Chevalier.
1994 - 1997Lecturer, Faculty of Medicine, University of Toronto.
1994 - 1995Clinical Research Fellow, NCIC Clinical Trials Group. Supervisors: Dr. Joseph L. Pater and Dr. Elizabeth Eisenhauer.
1994 - 1995Consultant, Kingston Regional Cancer Clinic.
1993FRCPC Certification in Medical Oncology.
1993 - 1994Medical Oncologist, St. Michael's Hospital, Department of Medicine.
1988MD, Magna Cum Laude, University of Ottawa.

Research Output

  • Dancey J. Early Clinical Trial Design Issues: Patient Populations, Endpoints and Barriers. In: Pandya KJ, Brahmer J, Hidalgo M, editors. Lung Cancer: Translational and Emerging Therapies. New York: Taylor & Francis Group, LLC; 2007.
  • Dancey J and Chen H
    Strategies for optimizing combinations of molecularly targeted anticancer agents
    • Nature Reviews Drug Discovery. 5:649-59; 2006
  • Dancey JE
    Predictive Factors for Epidermal Growth Factor Receptor Inhibitors – The Bull’s-Eye Hits the Arrow
    • Cancer Cell. 5:411-5; 2004
  • Dancey J and Sausville E
    Issues And Progress With Protein Kinase Inhibitors For Cancer Treatment
    • Nat Rev Drug Discov. 2:296-313; 2003
  • Dancey J, Freidlin B
    Agents Targeting EGFR: Are We Missing the Mark?
    • Lancet. 362:62-4; 2003